ArticleScientific reports2025
Core-shell silica and fluorogenic hyaluronan nanomaterials in magnesium hydroxyapatite scaffolds for bone regeneration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticle-Enabled Modulation of the Bone Immune Microenvironment for Enhanced Regeneration.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Nanomaterials represents a class of multifunctional materials that can play a key role in multiple applications of biomedicine. In case of severe bone defects due to trauma, cancer or aging, a huge demand for more effective treatments is one of the important challenges in clinical practice. Biomaterials for bone tissue engineering (BTE) is one of the appealing approach to enhance regenerative capability by combining several biocomponents like biomimetic materials and nanomaterials, cells, growth factors. Hydroxyapatite (HA) represents the most used based biomaterial for bone regeneration. However, there is still a crucial demand for new HA-based biomaterials satisfying clinical needs in terms of improved osteointegration and osteoregeneration. Here we show the synergic application of two nanomaterials, i.e., a fluorogenic hyaluronan nanogel (hyaluronic acid with Rhodamine B, HyRB) and a class of theranostic core–shell silica nanoparticles (PluSNPs) integrated into MgHA-type I collagen-based scaffolds. This novel biomaterial (HyRB/PluSNPs doped MgHA) showed improved performance in osteoregeneration, both for osteoconductivity and osteoinductivity; furthermore, the HyRB/PluSNPs nanomaterials can act as contrast agent for fluorescence imaging and have a potential for targeted drug delivery and for phototherapy. Results pave the way for the development of new multifunctional biomaterials combining the advantages of improved osteoconductivity/osteoinductivity of HyRB/PluSNPs with their potential drug delivery functionality and phototherapeutic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.